Whitehawk Therapeutics
Whitehawk Therapeutics' revenue fell 72.5% to $7 million in fiscal 2025. Its operating margin was −1,601.1%, down from −259.6% a year earlier. Free cash flow was −$98 million. The diluted share count rose 129.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Whitehawk Therapeutics lost money in fiscal 2025: a net loss of $21 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 149 | 173 | 109 | 47 | 146 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −167.2x | −272.5x | −311.4x | −438.0x | — |
| Current ratio | 9.9x | 9.6x | 4.7x | 3.6x | 10.3x |
| Quick ratio | 9.9x | 9.5x | 4.5x | 3.3x | 10.3x |
Cash flow
Projections
Project Whitehawk Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Whitehawk Therapeutics shares on the open market, and 3 insiders sold $2.6 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | Scott M. GiacobelloChief Financial Officer | Sold | 141,600 | $4.13 | $584,808 | Form 4 |
| Apr 15, 2026 | Scott M. GiacobelloChief Financial Officer | Sold | 77,000 | $3.86 | $297,220 | Form 4 |
| Apr 14, 2026 | Bryan BallSee remarks | Sold | 92,460 | $3.64 | $336,554 | Form 4 |
| Apr 13, 2026 | Bryan BallSee remarks | Sold | 26,389 | $3.46 | $91,306 | Form 4 |
| Apr 10, 2026 | Bryan BallSee remarks | Sold | 6,596 | $3.43 | $22,624 | Form 4 |
| Apr 9, 2026 | Bryan BallSee remarks | Sold | 50,000 | $3.57 | $178,500 | Form 4 |
| Apr 9, 2026 | David James LennonChief Executive Officer, Director | Sold | 14,500 | $3.38 | $49,010 | Form 4 |
| Apr 8, 2026 | David James LennonChief Executive Officer, Director | Sold | 63,945 | $3.40 | $217,413 | Form 4 |
| Apr 7, 2026 | David James LennonChief Executive Officer, Director | Sold | 94,087 | $3.43 | $322,718 | Form 4 |
| Apr 6, 2026 | David James LennonChief Executive Officer, Director | Sold | 102,395 | $3.51 | $359,406 | Form 4 |
| Apr 2, 2026 | David James LennonChief Executive Officer, Director | Sold | 26,858 | $3.48 | $93,466 | Form 4 |
| Mar 2, 2026 | David James LennonChief Executive Officer, Director | Sold | 5,100 | $3.31 | $16,881 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −201.2% | −228.9% | −1,443.9% |
| Altman Z'' | −1.35 | −14.66 | 2.98 |
| Accruals ratio | −3.9% | −4.1% | 69.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Whitehawk Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Whitehawk Therapeutics | FY25 | −72.5% | −1,601.1% | −1,371.4% | — | — | — | |
| Fate Therapeutics | FY25 | −51.2% | −2,222.4% | −1,685.8% | — | — | — | Compare |
| X4 Pharmaceuticals | FY25 | 150.0% | −1,336.7% | −1,317.2% | — | — | 3 | Compare |
| Korro Bio | FY25 | 181.5% | −1,906.4% | −1,237.2% | — | — | — | Compare |
| Roivant Sciences | FY25 | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 20 | 0 | 14 | 14 | 15 | 24 | 26 | 7 |
| Revenue growth | — | — | — | −100.0% | — | 0.0% | 8.7% | 60.1% | 6.7% | −72.5% |
| Gross profit | — | — | — | — | — | 14 | 14 | 22 | 23 | 6 |
| Research and development | 11 | 12 | 18 | 13 | 15 | 20 | 33 | 49 | 51 | 91 |
| Operating income | −17 | −21 | −11 | −24 | −2 | −111 | −63 | −72 | −68 | −114 |
| Net income | −17 | −21 | −10 | −23 | −4 | −110 | −60 | −66 | −64 | −21 |
| Diluted EPS (US$) | −24.52 | −1.03 | −0.31 | −0.57 | −1.76 | −12.41 | −2.69 | −2.44 | −2.36 | −0.33 |
| Diluted shares (millions) | 1 | 22 | 34 | 41 | 2 | 9 | 22 | 27 | 27 | 62 |
| Cash flow | ||||||||||
| Cash from operations | −0 | −19 | −6 | −24 | −13 | −22 | −50 | −60 | −60 | −97 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 1 |
| Free cash flow | −0 | −19 | −6 | −24 | −13 | −22 | −50 | −64 | −61 | −98 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 3 | 1 | 0 | 2 | 10 | 12 | 11 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | — | 63 | 38 | 4 | 149 | 173 | 109 | 47 | 146 |
| Debt incl. finance leases | — | — | — | — | 1 | — | — | — | — | — |
| Total assets | 2 | 21 | 64 | 40 | 19 | 158 | 184 | 132 | 70 | 151 |
| Total liabilities | 89 | 4 | 6 | 3 | 31 | 22 | 26 | 27 | 18 | 14 |
| Shareholders' equity | −86 | 17 | 59 | −9 | −12 | 136 | 158 | 105 | 52 | 136 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | 100.0% | 91.2% | 88.5% | 88.4% | 89.4% |
| Operating margin | — | — | −55.5% | — | −18.2% | −794.4% | −411.9% | −295.4% | −259.6% | −1,601.1% |
| Net margin | — | — | −51.6% | — | −24.8% | −786.4% | −397.7% | −270.0% | −245.1% | −288.3% |
| Free cash flow margin | — | — | −29.0% | — | −90.9% | −160.5% | −329.1% | −261.3% | −235.6% | −1,371.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −160.5% | −320.5% | −201.2% | −228.9% | −1,443.9% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −27.3% | −93.9% | — | −177.6% | −41.1% | −49.9% | −80.8% | −21.8% |
| Return on assets | −1,406.3% | −182.7% | −24.4% | −44.7% | −11.8% | −124.6% | −35.4% | −41.5% | −62.8% | −18.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |